Novartis will present late-breaking data from Phase III trials for ianalumab in Sjögren’s disease and biomarker data for rapcabtagene autoleucel in lupus at the 2025 ACR Convergence. The company aims to advance innovative medicines for autoimmune diseases with high unmet needs. Ianalumab could be the first targeted therapy for Sjögren’s disease, a condition with no FDA-approved treatments. Novartis plans to hold a virtual investor event post-ACR to highlight progress in its immunology pipeline. The data demonstrate Novartis’ dedication to developing new therapies for challenging autoimmune diseases like Sjögren’s. Novartis announces positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials for Sjögren’s disease, as well as biomarker data for CAR-T cell therapy in lupus. Virtual investor event planned post-ACR. Novartis emphasizes commitment to innovative medicines for autoimmune diseases. References available for further information on studies and trials. Novartis works to improve lives and empower patients worldwide. Visit their website or social media for more info. Novartis cautions about uncertainties in research, development, and regulatory actions. Stay updated with Novartis for future updates and progress in immunology pipeline.

Read more at Positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented, along with biomarker data on investigational CAR-T cell therapy rapcabtagene autoleucel (YTB323) in systemic lupus erythematosus. Novartis highlights commitment to advancing innovative medicines for autoimmune diseases with high unmet need, plans virtual investor event post-ACR. (GlobeNewswire): Novartis showcases significant immunology advancements in